Dr Markwin Velders is Vice President of Operations and Managing Director in Europe at Kite EU B.V., a Gilead Company.
Dr Velders has over 25 years’ experience in tumour immunology and immunotherapy, working in the fields of research, development and operations.
Dr Velders was awarded a PhD in Molecular Immunology from Leiden University in the Netherlands. During his studies he joined a research group at the Weizmann Institute in Israel, where the breakthrough discovery of the Chimeric T-cell receptor was made. Dr Velders then undertook postdoctoral research at Loyola University, Chicago, USA and became an Associate Professor in Molecular Immunology and Immunotherapy of Cancer.
After transferring to the biopharmaceutical sector Dr Velders spent three and a half years at Dutch company AM-Pharma, working in R&D and (pre)-clinical development. In 2013 he joined the Dutch biotech T-Cell Factory (TCF) where he played a key role in the acquisition of the company to form Kite Pharma EU B.V.Dr Velders joined Kite in 2015, where he oversees the research and development of new CAR T receptors alongside managing the implementation of Kite’s new manufacturing facility in the Netherlands. He is also the current chairman of the board of HollandBio, the branch association for biotech in the Netherlands, a position he has held since June 2017.